Drugs / Glipizide
Glipizide
also known as
CP-28,720 · Glibenese · Glipizida · Glipizide component of metaglip · Glipizide slow release · Glucotrol · Glucotrol xl · K 4024 · +3 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | GLUCOTROL XL | — | 1998-02-04 – 2002-04-01 | fda.gov ↗ |
| Approved | US (FDA) | GLUCOTROL | — | 1984-05-08 | fda.gov ↗ |
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT05159427 | Mar 2022 → Mar 2026 | — | University of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT01762046 | Jan 2008 → Dec 2015 | type 2 diabetes mellitus | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 1 | NCT00649454 | Jun 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00648505 | Jun 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00835497 | Jun 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00834587 | Jun 2004 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00947024 | Nov 1993 | type 2 diabetes mellitus | Sandoz | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06168812 | Dec 2023 → Dec 2026 expected | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00575588 | Dec 2007 → Aug 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00095056 | Oct 2004 → Jul 2006 | chronic renal failure syndrome, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04239586 | Apr 2017 → Apr 2022 | maturity-onset diabetes of the young type 1, maturity-onset diabetes of the young type 3, type 1 diabetes mellitus | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01951651 | Apr 2010 → Oct 2012 | type 2 diabetes mellitus | Baylor College of Medicine | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06830096 | Mar 2025 → Mar 2026 overdue | type 2 diabetes mellitus | Washington University School of Medicine | Recruiting | No outcome recorded |
| — | NCT02608177 | Nov 2015 → Aug 2017 | chronic kidney disease, type 2 diabetes mellitus | University of Washington | Completed | No outcome recorded |
| — | NCT01082796 | Nov 2009 → Jan 2010 | — | Chinese Academy of Sciences | Completed | No outcome recorded |
Also used as a comparator or background therapy in 21 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01020123 Comparator | Oct 2009 → Feb 2011 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT01698775 Background | Oct 2012 → Jan 2016 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00885352 Background | Apr 2009 → Nov 2010 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00856284 Comparator | Mar 2009 → Oct 2012 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00707993 Comparator | Jun 2008 → Aug 2010 | type 2 diabetes mellitus | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00660907 Comparator | Mar 2008 → Dec 2009 | type 2 diabetes mellitus | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT00509236 Comparator | Oct 2007 → Mar 2011 | end stage renal failure, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00509262 Comparator | Oct 2007 → Mar 2011 | chronic kidney disease, type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00350779 Background | Jun 2006 → Sep 2007 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00116831 Comparator | Jan 2005 → Aug 2008 | atherosclerosis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00094770 Comparator | Sep 2004 → May 2006 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 3 | NCT00086515 Comparator | Jun 2004 → Jul 2005 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 47 trials | ||||||
| Phase 4 | NCT06449235 Comparator | Sep 2024 → Apr 2025 overdue | type 2 diabetes mellitus | Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT02911792 Comparator | Dec 2016 → Jul 2023 | type 2 diabetes mellitus | The University of Texas Health Science Center at San Antonio | Completed | No outcome recorded |
| Phase 4 | NCT01267448 Comparator | Sep 2014 → Jul 2015 | hyperglycemia, type 2 diabetes mellitus | Cook County Health | Completed | No outcome recorded |
| Phase 4 | NCT01758471 Comparator | Dec 2012 → Dec 2013 | type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT00347100 Comparator | Jun 2006 → May 2008 | type 2 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00732524 Comparator | Sep 2004 → Apr 2006 | type 2 diabetes mellitus | Cook County Health | Completed | No outcome recorded |
| Phase 4 | NCT00513630 Comparator | Jun 2004 → Jul 2010 | coronary artery disorder, type 2 diabetes mellitus | Shanghai Jiao Tong University School of Medicine | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00691314 Comparator | Jun 2008 → Sep 2010 | atherosclerosis, transient ischemic attack | Peking Union Medical College Hospital | Completed | No outcome recorded |
| — | NCT00664846 Background | Apr 2008 → Dec 2010 | ischemic stroke | Peking Union Medical College Hospital | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2005-10-31 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Glipizide and Metformin HCL Tablets tevapharm.com ↗ |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 38 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Glipizide | “This Arm will include patients receiving Sulphonylureas (Gliclazide/ Glipizide/ Glimepiride/ Tolbutamide) according to the physician's choice.” NCT06449235 ↗35“Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)” NCT00575588 ↗ “Single dose of Glipizide (5 mg modified-release tablet) and Rifaximin (200 mg tablet)” NCT05159427 ↗ “antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid” NCT00691314 ↗ “antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid” NCT00664846 ↗ “Glipizide” NCT04239586 ↗ |
| Known as | CP-28,720 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Glibenese | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Glipizida | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Glipizide component of metaglip | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Glipizide slow release | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Glucotrol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Glucotrol xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | K 4024 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Minodiab 2.5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | Minodiab 5 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Known as | NSC-759120 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1073 ↗ |
| Action | Inhibit | “glipizide that inhibits KATP channels” NCT06830096 ↗ |
| Modality | Small molecule | “compared with the sulfonylurea glipizide” PMID 20194881 ↗ Mar 2010 |
| Route | Oral | “oral tablets of sitagliptin-matched placebo 100 mg and glipizide 5 mg” NCT00086515 ↗ |